Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study

Detalles Bibliográficos
Autores principales: Nakamura, Ichiro, Maegawa, Hiroshi, Tobe, Kazuyuki, Uno, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496576/
https://www.ncbi.nlm.nih.gov/pubmed/34279807
http://dx.doi.org/10.1007/s12325-021-01813-8
_version_ 1784579781014061056
author Nakamura, Ichiro
Maegawa, Hiroshi
Tobe, Kazuyuki
Uno, Satoshi
author_facet Nakamura, Ichiro
Maegawa, Hiroshi
Tobe, Kazuyuki
Uno, Satoshi
author_sort Nakamura, Ichiro
collection PubMed
description
format Online
Article
Text
id pubmed-8496576
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-84965762021-10-19 Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study Nakamura, Ichiro Maegawa, Hiroshi Tobe, Kazuyuki Uno, Satoshi Adv Ther Correction Springer Healthcare 2021-07-19 2021 /pmc/articles/PMC8496576/ /pubmed/34279807 http://dx.doi.org/10.1007/s12325-021-01813-8 Text en © Crown 2021 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Correction
Nakamura, Ichiro
Maegawa, Hiroshi
Tobe, Kazuyuki
Uno, Satoshi
Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
title Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
title_full Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
title_fullStr Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
title_full_unstemmed Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
title_short Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
title_sort correction to: safety and effectiveness of ipragliflozin for type 2 diabetes in japan: 12-month interim results of the stella-long term post-marketing surveillance study
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496576/
https://www.ncbi.nlm.nih.gov/pubmed/34279807
http://dx.doi.org/10.1007/s12325-021-01813-8
work_keys_str_mv AT nakamuraichiro correctiontosafetyandeffectivenessofipragliflozinfortype2diabetesinjapan12monthinterimresultsofthestellalongtermpostmarketingsurveillancestudy
AT maegawahiroshi correctiontosafetyandeffectivenessofipragliflozinfortype2diabetesinjapan12monthinterimresultsofthestellalongtermpostmarketingsurveillancestudy
AT tobekazuyuki correctiontosafetyandeffectivenessofipragliflozinfortype2diabetesinjapan12monthinterimresultsofthestellalongtermpostmarketingsurveillancestudy
AT unosatoshi correctiontosafetyandeffectivenessofipragliflozinfortype2diabetesinjapan12monthinterimresultsofthestellalongtermpostmarketingsurveillancestudy

Ejemplares similares